Dr. Maddocks on the Investigation of Noncovalent BTK Inhibitors in MCL
Kami J. Maddocks, MD, discusses the investigation of noncovalent BTK inhibitors in mantle cell lymphoma.
EP: 1.Dr. Kumar on Treatment Options for Patients Who Progress on a BTK Inhibitor in MCL
EP: 2.Dr. Lunning on Trials Evaluating BTK Inhibitors in CLL
EP: 3.Dr. Maddocks on the Investigation of Noncovalent BTK Inhibitors in MCL
EP: 4.Dr. Danilov on the Future of BTK Inhibitors in CLL
EP: 5.The Role of Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
EP: 6.Dr. Owen on Choosing Between BTK Inhibitors in CLL
EP: 7.Dr. Torka on the Role of Pirtobrutinib in R/R MCL
EP: 8.BTK Inhibitors in MCL and CLL
EP: 9.Dr. Phillips on BTK Inhibitor Selection in MCL
Kami J. Maddocks, MD, professor, the Division of Hematology at The Ohio State University, professor, member, the Leukemia Research Program, the OSUCCC – James, discusses the investigation of noncovalent BTK inhibitors in mantle cell lymphoma (MCL).
The role of noncovalent BTK inhibitors in patients with MCL continues to evolve, according to Maddocks. Most patients treated on clinical trials evaluating the use of noncovalent BTK inhibitors have either progressed on prior covalent BTK inhibitors or stopped treatment due to toxicity, Maddocks says. Data have suggested that noncovalent BTK inhibitors can potentially be leveraged in those who progress on covalent BTK inhibitors, Maddocks adds.
The phase 3 BRUIN-MCL-321 trial (NCT04662255) is investigating the noncovalent BTK inhibitor pirtobrutinib (LOXO-305) vs physician’s choice of covalent BTK inhibitors, including ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa), in pretreated patients with MCL, Maddocks concludes.
